UPPSALA, Sweden, June 1, 2026
Senzime AB announced the commercial launch of its next-generation TetraSens® electromyography (EMG) sensor, designed for use with the TetraGraph® Train-of-Four neuromuscular monitoring system. The newly introduced sensor combines enhanced sustainability, clinical performance, and ease of use, supporting healthcare providers seeking objective neuromuscular monitoring solutions. The product is now commercially available across European markets and is scheduled for launch in the United States during the third quarter of 2026.
New Sensor Design Improves Sustainability and Efficiency
Senzime’s new TetraSens sensor utilizes 50% less dielectric material compared to previous-generation sensors while maintaining the same trusted performance standards relied upon by anesthesia providers worldwide. The sensor is manufactured in Europe using an environmentally responsible production process that incorporates a regional supply chain, reduced transportation distances, and optimized packaging solutions. These sustainability-focused improvements align with growing healthcare industry efforts to reduce environmental impact without compromising patient care quality or clinical performance.
Enhanced Usability Supports Accurate Patient Monitoring
The latest TetraSens sensor also introduces an improved visual guidance system designed to help clinicians achieve faster, more consistent patient sensor placement. This enhancement supports more efficient workflow during surgical procedures while helping maintain accurate neuromuscular monitoring. The new sensor design is protected by both European Union and United States patents, reinforcing Senzime’s commitment to innovation in perioperative monitoring technologies. According to the company, development of the sensor incorporated insights gained from more than one million monitored clinical cases.
Advertisement
Strengthening Quantitative Neuromuscular Monitoring Adoption
The launch expands Senzime’s portfolio of quantitative neuromuscular monitoring solutions aimed at improving patient safety during anesthesia and recovery. The company’s flagship TetraGraph® system is widely used in operating rooms globally to monitor neuromuscular transmission, helping clinicians optimize paralytic drug dosing and reduce the risk of residual neuromuscular blockade. Senzime believes the new TetraSens sensor will support hospitals seeking to standardize objective neuromuscular monitoring practices in accordance with evolving clinical guidelines and institutional protocols, while also advancing healthcare sustainability initiatives.
Source: Senzime press release
